Skip to main content

Mosaic ImmunoEngineering Inc.

For the period ended Dec 31, 2024. Filed Apr 15, 2025.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Apr 15, 2025

CPMVStored price and day change unavailable

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Item 8. Consolidated Statements of Cash Flows

Consolidated Statements of Cash Flows

Year Ended December 31,
20242023
Operating activities:
Net loss$(921,983)$(1,008,235)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation4,86721,935
Gain on redemption of preferred stock of Holocom–(433,000)
Change in fair value of derivative liability–(46,700)
Non-cash interest on convertible notes73,53373,333
Accretion to redemption value on convertible notes1,44615,842
Changes in operating assets and liabilities:
Prepaid expenses and other current assets(3,237)17,277
Accounts payable16,387(14,986)
Accrued compensation582,741785,779
Accrued consulting–34,333
Accrued expenses and other5,08756,955
Net cash used in operating activities(241,159)(497,467)
Investing activities:
Proceeds from redemption of preferred stock of Holocom–433,000
Net cash provided by investing activities–433,000
Financing activities:
Proceeds from the issuance of loans payable270,000–
Payments on loan payables(70,000)–
Net cash provided by financing activities200,000–
Net change in cash and cash equivalents(41,159)(64,467)
Cash and cash equivalents, beginning of period156,178220,645
Cash and cash equivalents, end of period$115,019$156,178
Supplemental disclosure of cash flow information:
Cash paid for income taxes$2,400$2,400
Cash paid for interest on loan payable$6,214$–

Mosaic ImmunoEngineering, Inc.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.